The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 40 | — | 20.1x | Near average | |
Growth | 20 | -100.0% | 5.6% | Below average | |
Quality | 10 | -174.1% | 7.6% | Below average | |
Safety | 36 | 1.3x | 0.4x | Near average | |
Capital Return | 27 | — | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Molecular Partners AG is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Molecular Partners AG shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Molecular Partners stock shows a state of total stability in its price target at 13 dollars, representing a significant premium compared to the current price (4.18 dollars). Forecasts have seen no changes over the past 7 and 30-day periods, indicating an absence of new catalysts or analyst revisions in the recent period.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.